

HEMADY (dexamethasone tablets)

RATIONALE FOR INCLUSION IN PA PROGRAM

Background

Hemady (dexamethasone) is a corticosteroid with anti-inflammatory effects and low mineralocorticoid activity. Dexamethasone induces apoptosis in multiple myeloma cells (1).

Regulatory Status

FDA-approved indication: Hemady is a corticosteroid indicated in combination with other anti-myeloma products for the treatment of adults with multiple myeloma (1).

The recommended dosage of Hemady is 20 mg or 40 mg, orally, once daily, on specific days depending on the treatment regimen. Refer to the Prescribing Information of other anti-myeloma products used in combination with Hemady for specific Hemady dosing (1).

Hemady can cause fetal harm when administered to a pregnant woman. Females of reproductive potential should be advised to use effective contraception during treatment with Hemady and for at least 1 month after the last dose (1).

The safety and effectiveness of Hemady in pediatric patients have not been established (1).

Summary

Hemady (dexamethasone) is a corticosteroid with anti-inflammatory effects and low mineralocorticoid activity. Dexamethasone induces apoptosis in multiple myeloma cells. The safety and effectiveness of Hemady in pediatric patients have not been established (1).

Prior authorization is required to ensure the safe, clinically appropriate, and cost-effective use of Hemady while maintaining optimal therapeutic outcomes.

References

1. Hemady [package insert]. Parsippany, NJ: Edembridge Pharmaceuticals, LLC; June 2023.